Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Level BiotechnologyROCO:3118 77 Days Payable is 40.83 as of Dec. 2025, which is 20% below its 10-year median of 51.33. GuruFocus rates ROCO:3118 with a GF Score™ of 77/100 and a GF Value™ of NT$35.57 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 702 Biotechnology companies, Level Biotechnology ranks worse than 76.07% on this metric.
The historical rank and industry rank for Level Biotechnology's Days Payable or its related term are showing as below:
ROCO:3118'
s Days Payable Range Over the Past 10 Years
Min: 36.93 Med: 51.33 Max: 64.26
Current: 36.93
During the past 13 years, Level Biotechnology's highest Days Payable was 64.26. The lowest was 36.93. And the median was 51.33.
ROCO:3118's Days Payable is ranked worse than 76.07% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs ROCO:3118: 36.93
Level Biotechnology's Days Payable
increased
from Dec. 2024 (34.17) to Dec. 2025 (40.83).
It may suggest that Level Biotechnologydelayed paying its suppliers.
Level Biotechnology Days Payable Related Terms
Level Biotechnology Days Payable Historical Data
* Premium members only.
The historical data trend for Level Biotechnology's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3118 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Level Biotechnology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Level Biotechnology Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Level Biotechnology's Days Payable distribution charts can be found below:
* The bar in red indicates where Level Biotechnology's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Level Biotechnology's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Level Biotechnology (ROCO:3118) has a Days Payable of 40.83 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Level Biotechnology and its competitors. This is 20% below median its historical median of 51.33. Over the past decade, Level Biotechnology's Days Payable has ranged from 36.93 to 64.26. According to the industry distribution chart, Level Biotechnology ranks #534 out of 702 companies in the Biotechnology industry, placing it in the top 76.1%.
Is Level Biotechnology's Days Payable too high?
Level Biotechnology's current Days Payable of 40.83 is 20% below median its 10-year median of 51.33. Over the past 10 years, this metric has ranged from a low of 36.93 to a high of 64.26. The Biotechnology industry median Days Payable is 113.10. Level Biotechnology's value of 40.83 is 63.9% below this industry median. Based on the distribution chart, Level Biotechnology ranks #534 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Level Biotechnology has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Level Biotechnology's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Level Biotechnology ranks #534 out of 702 companies for Days Payable. This places Level Biotechnology in the lower half of its industry. The industry median Days Payable is 113.10. Level Biotechnology's value of 40.83 is 63.9% below this benchmark. Historically, Level Biotechnology's own Days Payable has ranged from 36.93 to 64.26 over the past decade. While the company's 10-year median is 51.33 vs. the industry median of 113.10, Level Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Level Biotechnology's current Days Payable of 40.83 is 63.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Level Biotechnology and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Level Biotechnology's current Days Payable is 40.83, which is 20% below median its own 10-year median of 51.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Level Biotechnology (ROCO:3118) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$35.57, compared to a current price of NT$31.75 — trading 10.7% below its estimated fair value. The current Days Payable is 40.83, which is 20% below median its 10-year median of 51.33 and 63.9% below the Biotechnology industry median of 113.10. Level Biotechnology's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Level Biotechnology (ROCO:3118), the current Days Payable is 40.83 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Level Biotechnology (ROCO:3118) Overvalued in 2026?
Based on GuruFocus' analysis, Level Biotechnology stock appears to be undervalued.
The current stock price of NT$31.75 is trading 10.7% below its estimated GF Value™ of NT$35.57.
GuruFocus considers Level Biotechnology to be Modestly Undervalued.
Key valuation signals for ROCO:3118:
Days Payable: 40.83 (20% below median its 10-year median of 51.33)
GF Value™: NT$35.57 vs. price of NT$31.75 (10.7% below fair value)
Industry Position: 63.9% below the Biotechnology median (#534 of 702)
No single metric tells the full story. See the ROCO:3118 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Level Biotechnology Inc is a Taiwan-based company engaged in the sales of biomedical products and providing preclinical testing services. The company has three reportable segments: Department A and B, Department C, and Department D. Department A and Department B sell the cell culture consumables and the antibody reagents, Department C sells the instruments and equipment, and Department D provides CRO services. The majority of revenue is derived from the Department A and B.
77GF Score
Get the complete analysis for ROCO:3118
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3118 has been successfully added to your 
